Deleterious genetic influence of CX3CR1 genotypes on HIV-1 disease progression

被引：27

作者：

Faure, S

Meyer, L

Genin, E

Pellet, P

Debré, P

Théodorou, I

Combadière, C

机构：

[1] Hop La Pitie Salpetriere, INSERM U543, Paris, France

[2] INSERM, U569, Serv Epidemiol, Le Kremlin Bicetre, France

[3] Hop Bicetre, Fac Med, INSERM, U535, Le Kremlin Bicetre, France

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2003年 / 32卷 / 03期

关键词：

HIV; chemokine; CX3CR1; polymorphism;

D O I：

10.1097/00126334-200303010-00014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We previously reported that patients homozygous for a specific mutation (M280) in the chemokine receptor CX3CR1 progressed to AIDS more rapidly than those with other genotypes. This deleterious effect would predict that a cohort of prevalent patients would be depleted in M280 carriers, because these patients would have disappeared before recruitment. This hypothesis is confirmed ill this new Study based on the French SEROCO cohort showing that patients homozygous for the M280 allele were rare among the seroprevalent group. These results may explain the conflicting results published on the impact of CX3CR1 polymorphism in seroconverters.

引用

页码：335 / 337

页数：3

共 50 条

[11] Common CX3CR1 alleles are associated with a reduced risk of headaches
Combadiere, Christophe
Godin, Ophelia
Vidal, Cecile
Cangialosi, Arnaud
Proust, Carole
Tzourio, Christophe
HEADACHE, 2008, 48 (07): : 1061 - 1066
[12] Pancreatic Stellate Cells and CX3CR1 Occurrence in Normal Pancreas and Acute and Chronic Pancreatitis and Effect of Their Activation by a CX3CR1 Agonist
Uchida, Masahiko
Ito, Tetsuhide
Nakamura, Taichi
Hijioka, Masayuki
Igarashi, Hisato
Oono, Takamasa
Kato, Masaki
Nakamura, Kazuhiko
Suzuki, Koichi
Takayanagi, Ryoichi
Jensen, Robert T.
PANCREAS, 2014, 43 (05) : 708 - 719
[13] Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1 - A genetic risk factor
Ghilardi, G
Biondi, ML
Turri, O
Guagnellini, E
Scorza, R
STROKE, 2004, 35 (06) : 1276 - 1279
[14] Downregulation of CX3CR1 ameliorates experimental colitis: evidence for CX3CL1-CX3CR1-mediated immune cell recruitment
Becker, Felix
Holthoff, Christina
Anthoni, Christoph
Rijcken, Emile
Alexander, J. Steven
Gavins, Felicity N. E.
Spiegel, H. U.
Senninger, Norbert
Vowinkel, Thorsten
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2017, 32 (03) : 315 - 324
[15] CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes
Liu, Che
Luo, Defang
Streit, Wolfgang J.
Harrison, Jeffrey K.
JOURNAL OF NEUROIMMUNOLOGY, 2008, 198 (1-2) : 98 - 105
[16] Bone marrow-derived CX3CR1 progenitors contribute to neointimal smooth muscle cells via fractalkine CX3CR1 interaction
Kumar, Arun H. S.
Metharom, Pat
Schmeckpeper, Jeff
Weiss, Sharon
Martin, Kenneth
Caplice, Noel M.
FASEB JOURNAL, 2010, 24 (01) : 81 - 92
[17] Role of CX3CR1 signaling in malignant transformation of gliomas
Lee, Sungho
Latha, Khatri
Manyam, Ganiraju
Yang, Yuhui
Rao, Arvind
Rao, Ganesh
NEURO-ONCOLOGY, 2020, 22 (10) : 1463 - 1473
[18] Two polymorphisms in the fracalkine receptor CX3CR1 are not associated with peripheral arterial disease
Gugl, A
Renner, W
Seinost, G
Brodmann, M
Pabst, E
Wascher, TC
Paulweber, B
Iglseder, B
Pilger, E
ATHEROSCLEROSIS, 2003, 166 (02) : 339 - 343
[19] Involvement of the CX3CL1 (fractalkine)/CX3CR1 pathway in the pathogenesis of acute graft-versus-host disease
Brissot, Eolia
Bossard, Celine
Malard, Florent
Braudeau, Cecile
Chevallier, Patrice
Guillaume, Thierry
Delaunay, Jacques
Josien, Regis
Gregoire, Marc
Gaugler, Beatrice
Mohty, Mohamad
JOURNAL OF LEUKOCYTE BIOLOGY, 2015, 97 (02) : 227 - 235
[20] CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?
Zhuang, Quan
Cheng, Ke
Ming, Yingzi
CURRENT GENE THERAPY, 2017, 17 (06) : 442 - 452

← 1 2 3 4 5 →